Page 1

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update ● ● Continuation of corporate transformation into commercial - ready biopharma company Management team strengthened with appointments of Chief Operating Officer Malte Greune and Chief Development Officer Klaus Edvardsen First - generation COVID - 19 vaccine candidate , CVnCoV O O UREVAC the RNA people O Final analysis reported of pivotal Phase 2b / 3 study conducted in ten countries in variant - dominated environment Second - generation COVID - 19 vaccine candidate , CV2COV , jointly advanced with GSK Preclinical study provides evidence for strongly improved immune responses with second - generation mRNA backbone compared to first - generation backbone during challenge study and against range of variants , including Delta and Lambda variant Start of CV2COV Phase 1 clinical trial anticipated in Q4 2021 Oncology Programs Committed to seeking regulatory approval with EMA - submission of comprehensive clinical data packages within rolling submission ongoing ● Financials : Cash position of € 1.36 billion as of June 30 , 2021 Phase 1 trial extension of lead asset , CV8102 , on track to fully recruit Legacy program , Bl 1361849 , developed in partnership with Boehringer Ingelheim , based on early protamine formulation terminated ; companies assessing options for further collaboration TÜBINGEN , Germany / BOSTON , USA - August 16 , 2021 CureVac N.V. ( Nasdaq : CVAC ) , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ( " mRNA " ) , today announced financial results for the second quarter and first half of 2021 and provided business update . " Large parts of the world are still under - vaccinated against SARS - CoV - 2 , making effective vaccines necessary to prevent further evolution of the virus and to avoid renewed restrictions on public life , " said Franz - Werner Haas , Chief Executive Officer of CureVac . " While the recently reported final data from our pivotal Phase 2b / 3 study have fallen short of expectations in older adults , our first generation COVID - 19 vaccine candidate , CVnCoV , has shown a solid efficacy profile in the age group of 18 to 60. We are reaffirming our intention to seek regulatory approval with the European Medicines agency and are currently submitting extensive clinical data to the agency to allow for the assessment of CVnCoV's public health benefit . Insights from our COVID - 19 development program are feeding into all areas of our pipeline , where we are pursuing a broader technology approach and multivalent as well as combination vaccine formats , as part of the large infectious diseases program jointly developed with GSK . This includes our second - generation COVID - 19 vaccine candidate , CV2COV , which is advancing on track to enter clinical development in Q4 2021. In parallel , we are accelerating the development of the organization and the expansion of our manufacturing capacity , including the capacity for more clinical trials , while creating a strong development focus for The RNA Printer® via a separate operational infrastructure for this strategic key project . "